Quoin launches Netherton NOW campaign for rare disease awareness

Quoin Pharmaceuticals, Ltd.

Campaign 'NETHERTON NOW' launched Feb 4, 2025 to raise awareness for Netherton Syndrome.
20% of babies with Netherton Syndrome estimated not to survive, per company.
Quoin has four ongoing clinical studies evaluating QRX003 for Netherton Syndrome.
As of Feb 4, 2025, outstanding ordinary shares (ADS) total 20,585,830.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.